ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0716

Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic

Jack Ellrodt1, Emily G Oakes1, Laura Kubzansky2, Karestan Koenen2, Hongshu Guan1 and Karen Costenbader1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard TH Chan School of Public Health, Boston, MA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, mental health, psychological status, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Posttraumatic Stress Disorder (PTSD), a complex psychiatric disorder that can result from experiencing or witnessing a traumatic event, such as an accident, assault, or death. We aimed to assess the prevalence of PTSD symptoms at the onset of the COVID-19 pandemic among individuals with or without systemic autoimmune rheumatic disease (SARD) diagnoses, given the increased stress those with SARDs may have experienced given their immunosuppression.

Methods: In May 2020, at the start of the COVID-19 pandemic, we invited 6,681 patients of a large multihospital system who had opted in to research opportunities (including 378 with ≥ 2 ICD 9/10 prior PTSD codes) to complete the Brief Trauma Questionnaire and the Posttraumatic Stress Disorder Checklist (PCL-5). The Brief Trauma Questionnaire and the PCL-5 are previously validated questionnaires that can identify individuals with probable PTSD. Diagnoses for prior PSTD, SARD, anxiety, depression, and adjustment disorders were identified using ICD-9/10 billing code algorithms. Survey responses were analyzed using univariable t-tests to identify differences between SARDs and non-SARDs subjects. We used multivariable logistic regression to identify potential predictors of PCL-5 positivity, an indication for PTSD, at the time of survey distribution.

Results: We received 1,411 complete and unique responses (21% response rate) between 5/2020 and 9/2021, with most responses received in late May to early June 2020. Of these respondents, 60 had a history of PTSD prior to the pandemic and 131 had a prior history of a SARD (Table 1). In the univariable analysis, the SARDs population was significantly more female (p< 0.0001) and had a higher baseline prevalence of anxiety, depression, and adjustment disorders (p=0.0008) than respondents without SARDs. In the early pandemic, there were no significant differences in PCL-5 scores (p=0.59), PCL-5 positivity (p=1.00), or traumatic events (p=0.47) between those with and without a SARDs diagnosis. Upon adjusting for pre-pandemic PTSD diagnoses, we found younger age (OR=0.97, 95% CI [0.96, 0.98] per increasing year) and history of anxiety, depression, or adjustment disorder (OR=2.25, 95% CI [1.68, 3.01]) to be the most significant predictors of PCL-5 positivity during the early pandemic (Table 2).

Conclusion: While SARDs was not a significant predictor of new onset PTSD symptoms, we found that younger individuals and those with a history of baseline anxiety, depression, or adjustment disorders, which were more common pre-pandemic among those with SARDs, were more likely to screen positive on the PCL-5 during early COVID-19 pandemic. The lack of increased PTSD symptoms in SARDs vs. non-SARDs populations suggests that during the early months of the pandemic, SARDs patients may not have been at higher risk for new PTSD symptoms.

Supporting image 1

Supporting image 2


Disclosures: J. Ellrodt, None; E. Oakes, None; L. Kubzansky, None; K. Koenen, None; H. Guan, None; K. Costenbader, Eli Lilly, Janssen, Amgen, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline(GSK), Gilead, Exagen, Neutrolis, Cel-Sci, Alkermes.

To cite this abstract in AMA style:

Ellrodt J, Oakes E, Kubzansky L, Koenen K, Guan H, Costenbader K. Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/posttraumatic-stress-disorder-symptoms-in-systemic-autoimmune-rheumatic-disease-patients-during-the-early-covid-19-pandemic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/posttraumatic-stress-disorder-symptoms-in-systemic-autoimmune-rheumatic-disease-patients-during-the-early-covid-19-pandemic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology